Health Snapshot: This One Blood Test Could Detect Multiple Cancers And Organ Damage
A pioneering breakthrough in medical diagnostics could soon allow doctors to screen for multiple cancers, liver conditions, and organ damage using a single, affordable blood test. Known as MethylScan, this innovative method developed by researchers at the University of California, Los Angeles (UCLA) extracts vital health signals from tiny genetic fragments circulating in the human bloodstream.
By dramatically lowering sequencing costs, the assay offers a promising, non-invasive alternative to complex scans and painful biopsies, paving the way for accessible routine health monitoring.
How MethylScan Decodes Blood Signals
Every day, billions of cells naturally die and release microscopic fragments of genetic material into the blood, known as cell-free DNA (cfDNA). While traditional liquid biopsies search for specific gene mutations—requiring expensive and deep DNA sequencing—MethylScan focuses instead on DNA methylation.
DNA methylation refers to chemical tags attached to genetic material that regulate how genes function. These chemical signatures change dramatically depending on the specific organ and whether the tissue is healthy or diseased.
Overcoming the ‘Background Noise’ Barrier
A major challenge in blood-based screening is that 80 to 90 per cent of circulating DNA originates from normal blood cells, creating heavy “background noise" that masks subtle signs of early disease.
MethylScan solves this by using specialised enzymes to selectively filter out unmethylated DNA from blood cells before sequencing. This clever filtering step enriches the sample for organ-derived signals, reducing the required sequencing data and bringing estimated sequencing costs down to under $20 per sample.
High Accuracy Across Cancers and Liver Conditions
In a study analysing blood samples from over 1,000 participants, the test demonstrated remarkable accuracy across several clinical areas:
- Multi-Cancer Detection: Achieved a 98% specificity rate, correctly detecting 63% of cancers overall—including lung, liver, stomach, and ovarian malignancies—and catching 55% of early-stage tumours.
- Pinpointing the Source: The test successfully identified the specific tissue of origin, directing clinicians straight to the affected organ.
- Liver Cancer Surveillance: Detected nearly 80% of liver cancer cases in high-risk individuals suffering from cirrhosis or hepatitis B.
- Classifying Liver Disease: Correctly distinguished between different liver conditions—such as viral hepatitis and metabolic-associated fatty liver disease—with 85% accuracy.
The Path Forward for Early Diagnosis
Catching diseases at Stage 1 rather than Stage 4 drastically improves long-term survival rates. By offering a low-cost, comprehensive snapshot of organ health, MethylScan could eventually transform annual check-ups, catching silent diseases long before symptoms appear. Larger clinical trials are now underway to validate its performance in real-world healthcare settings.
Key Questions Answered
MethylScan could eventually transform annual check-ups by detecting multiple cancers and organ damage before symptoms appear. However, the current reporting does not state that it will replace traditional cancer screening methods soon.